New shot aims to slash Sky-High cholesterol in rare genetic disease
NCT ID NCT07591298
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests an injection called SYH2070 in 18 Chinese adults with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition causing extremely high cholesterol. Participants receive the drug for 48 weeks to see if it safely lowers their LDL cholesterol levels. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SYH2070 injection
- What this could lead to
- If it works, this could offer a new treatment option to lower dangerously high cholesterol in people with homozygous familial hypercholesterolemia.
- What could go wrong
- This is an early Phase 2 trial with only 18 participants, so results may not apply broadly. The drug may not effectively lower cholesterol or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIAGNOSED WITH HOFH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••